Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000516427 | SCV000613255 | likely benign | not specified | 2017-03-24 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000726975 | SCV000704601 | uncertain significance | not provided | 2017-01-03 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000726975 | SCV000972837 | likely benign | not provided | 2020-10-13 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001081000 | SCV001004361 | likely benign | X-linked Emery-Dreifuss muscular dystrophy | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002350136 | SCV002643405 | likely benign | Cardiovascular phenotype | 2021-03-20 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Natera, |
RCV001834665 | SCV002084697 | benign | Emery-Dreifuss muscular dystrophy | 2019-10-22 | no assertion criteria provided | clinical testing |